Ir para o conteúdo principal

Infelizmente, não oferecemos suporte total ao seu navegador. Se for possível, atualize para uma versão mais recente ou use o Mozilla Firefox, o Microsoft Edge, o Google Chrome ou o Safari 14 ou mais recente. Se não conseguir e precisar de suporte, envie seu feedback.

Gostaríamos de receber seu feedback sobre essa nova experiência.Diga-nos sua opiniãoabre em uma nova guia/janela

Elsevier
Publique conosco

Alyson Kelvin

AK

Alyson Kelvin

University of Saskatchewan, Canada

Alyson Kelvin, PhD. Dr. Kelvinabre em uma nova guia/janela is a Scientist II at the Vaccine and Infectious Disease Organization (VIDO)abre em uma nova guia/janela, Saskatoon, Canada. She completed her HBSc at Western University (London, Canada, 2003) and her PhD at Queen’s University (Belfast, Northern Ireland, 2007). Dr. Kelvin’s expertise is in the fields of virology and vaccinology specifically focusing on the development of broadly protective vaccines for emerging viruses. She has researched several high-profile emerging viruses including the 2009 H1N1 pandemic influenza virus, avian H5N1 influenza virus, Mpox virus, SARS-CoV, and SARS-CoV-2. She is a member of expert panels for the control of emerging viruses including the Public Health Agency of Canada’s (PHAC) Avian Influenza Expert Panel. Dr. Kelvin has been recognized with a CEPI-CIHR Leadership Award in Vaccine Research as well as the Canadian Society for Virology Early Career Award of Excellence.